Monday, October 22, 2018, Boston - Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in the applications of the generative adversarial networks (GANs) and reinforcement learning (RL) for generation of novel molecular structures at the AI Applications in Biopharma Summit in Boston, 25-26 of October.
Generative Adversarial Networks (GANs) are considered one of the most relevant and interesting inventions in modern AI. Since the emergence in 2014 GANs have become widely known for their application versatility and outstanding results in generating data. The presentation will explore the application of GANs for the generation of molecules with specific properties and generation of molecules to a specific objective.
"GANs and GAN-RL systems are powerful tools that helped revolutionize drug discovery and biomarker development applications. At Insilico Medicine we have conducted a series of theoretical and experimental research studies in order to develop the models that could be employed in drug discovery process", says Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
The AI Applications in Biopharma Summit 2018 brings together the biopharmaceutical community to share the experiences, discuss obstacles, opportunities for partnerships, and the strategies used to implement AI technologies in the discovery and drug development process. The Summit is held on 25-26 of October 2018.
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine.
For further information, images or interviews, please contact:
Contact: Klug Gehilfer
Official website of the conference: https:/
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered at in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/